Trial Profile

Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary) ; Methotrexate
Indications Ankylosing spondylitis
Focus Pharmacodynamics
Acronyms COMARIS

Most Recent Events

22 Dec 2025 Actual primary completion date changed from 1 Apr 2015 to 27 Apr 2015.
15 Jun 2019 Results(n=104) presented at the 20th Annual Congress of the European League Against Rheumatism
28 Sep 2015 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com